IN8bio, Inc. (NASDAQ:INAB – Get Free Report) was the recipient of a significant decrease in short interest in the month of October. As of October 30th, there was short interest totaling 15,733 shares, a decrease of 52.0% from the October 15th total of 32,797 shares. Based on an average daily trading volume, of 36,207 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.2% of the company’s shares are sold short.
IN8bio Price Performance
Shares of NASDAQ:INAB traded down $0.00 on Friday, hitting $0.82. 7,622 shares of the company’s stock were exchanged, compared to its average volume of 35,660. The stock has a market capitalization of $8.86 million, a price-to-earnings ratio of -0.81 and a beta of 0.27. IN8bio has a 12 month low of $0.80 and a 12 month high of $2.73. The business’s 50 day simple moving average is $1.10 and its two-hundred day simple moving average is $1.39.
IN8bio (NASDAQ:INAB – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.10. Equities analysts forecast that IN8bio will post -1.49 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of IN8bio in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, IN8bio currently has a consensus rating of “Hold”.
Read Our Latest Report on INAB
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation.
Featured Stories
- Five stocks we like better than IN8bio
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.
